MassBioEd Events
Please view the discount options for courses before registering here.
-
Intro to Biotech Package Member: $1,550
-
Intro to Biotech Package Non-Member: 1,800
-
Member Rate: $850
-
Non-Member Rate: $1,025
Description
The Intro to Biotech course is divided into two parts: Intro to Business and Intro to Science. We provide a significant discount when individuals take the course as a package. While you can choose to attend one or the other, we highly recommend taking the course as a package to learn a more in-depth understanding of the biotech world.
Intro to Science explore considerations that drive company strategies. Students will be provided with foundational information about the biopharma industry and regulation via instruction, storytelling, and small group discussions. Industry ethics will be discussed, with emphasis on historical precedents. The course touches on topics such as market share, phases of development, patient population, safety profile, and more.
Date & Time
Intro to Science:
- Monday, December 2nd, 2024, 09:00 AM – 11:30 AM EST
- Wednesday, December 4th, 2024, 09:00 AM – 11:30 AM EST
- Thursday, December 5th, 2024, 09:00 AM – 11:30 AM EST
Intro to Business:
- Monday, December 9th, 2024, 09:00 AM-11:30 AM EST
- Wednesday, December 11th, 2024, 09:00 AM-11:30 AM EST
- Thursday, December 12th, 2024, 09:00 AM-11:30 AM EST
Instructors
Sowmya Chary, MD, MMSc
Associate Medical Director, Global Medical Safety and R&D, Biogen
Science
Sowmya is a Medical Director in Global Medical Safety at Biogen, focusing in the Neuromuscular and Movement Disorders Therapeutic Area. A Massachusetts native, she completed her medical training at Sri Ramachandra University in India and received her Master of Medical Sciences in Clinical Investigation from Harvard Medical School. She completed her thesis work at the Brigham and Women’s Hospital on sex-specific differences in metabolomic profiles and responses to intervention in the critically ill. Sowmya is a Fellow at the Harvard Medical School Center for Bioethics and serves on the Boston Board of Peer Health Exchange, an organization improving health equity and outcomes for young people in under-resourced communities. She is a passionate educator and mentor and has given numerous talks on navigating career paths and roles in the biotechnology/pharmaceutical industry. She brings her medical, research, and industry expertise to the classroom to create an engaging and collaborative learning environment.
John Tagliamonte
Chief Executive Officer, Mellitus
Business
John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies. As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu. Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.
Atul Deshpande, Ph.D., MBA
Chief Strategy Officer, Peptilogics
Business
Atul Deshpande is the Chief Strategy Officer at Peptilogics, a clinical stage AI/ML driven peptide therapeutics company, where he is responsible for corporate strategy and business development. Prior to that he was the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world. Atul spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma. Atul holds a Ph.D. from UC Irvine in Neuroscience and a post-doc from UCLA.